DaVita Inc.
DVA | NYSE
$182.76
-$4.74 (-2.53%)
Nov 2, 2026, 9:51 AM ET · Market open
Company Profile
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Key Executives
| Name | Position |
|---|---|
| Javier J. Rodriguez | Chief Executive Officer & Executive Director |
| David Maughan | Chief Operating Officer of DaVita Kidney Care |
| Joel Ackerman | Chief Financial Officer & Treasurer |
| Stephanie Hendrickson | Chief People Officer |
| Christopher Michael Berry | Group Vice President & Chief Accounting Officer |
| James O. Hearty | Chief Compliance Officer |
| Jeffrey Allen Giullian | Chief Medical Officer of Kidney Care |
| Kathleen Alyce Waters | Chief Legal & Public Affairs Officer |
| Misha Palecek | Chief Transformation Officer of U.S. Kidney Care Business |
| Nic Eliason | Group Vice President of Investor Relations |
DaVita Inc.
| Country | United States |
| IPO Date | Oct 31, 1995 |
| Industry | Medical - Care Facilities |
| Sector | Healthcare |
| Employees | 78,000 |
| CEO | Javier J. Rodriguez |
Contact Details
2000 16th Street Denver,
Colorado 80202 United States
Stock Details
| Ticker Symbol | DVA |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000927066 |
| CUSIP Number | 23918K108 |
| ISIN Number | US23918K1088 |
| SIC Code | 8090 |
Recent News
- 3 days ago / zacks.comDaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y
- 3 days ago / marketbeat.comWhat DaVita (DVA) Said on Its Q3 Earnings Call
- 3 days ago / seekingalpha.comDaVita Inc. (DVA) Q3 2026 Earnings Call Transcript
- 3 days ago / zacks.comDaVita HealthCare (DVA) Beats Q3 Earnings and Revenue Estimates
- 3 days ago / benzinga.comDaVita Q3 2026 Earnings Call Transcript
- 3 days ago / prnewswire.comDaVita Inc. 3rd Quarter 2026 Results
- 6 days ago / zacks.comWill DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?
- 6 days ago / prnewswire.comDaVita Brings Preventive Health Screenings Into Communities to Help Identify Hidden Health Risks
- 10 days ago / zacks.comDaVita HealthCare (DVA) Falls More Steeply Than Broader Market: What Investors Need to Know
- 11 days ago / zacks.comDaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?
Add to Watchlist
Select watchlists to add or remove DVA